Headline | Published Date | Published Price | Maximum Price Since Publication | Last Closing Price | Max Gain % |
TRVI - Trevi Completes Enrollment In PRISM Trial; Data Expected In Q2 | Feb. 1 | $0.70 | $4.68 | $2.24 | 569% |
APDN - APDN Soars On News Of Initiating Analytical Validation Of Diagnostic Test For Monkeypox Virus | Aug. 2 | $1.33 | $7.35 | $1.45 | 453% |
BEAT - Will FDA's Decision Be Music To BEAT's Ears? | Jun. 16 | $1.24 | $6.74 | $5.85 | 444% |
NRSN - What's Making News At NeuroSense? | Feb. 28 | $1.76 | $8.18 | $1.51 | 365% |
COGT - Will Cogent Biosciences Reach The APEX And PEAK? | May. 16 | $4.02 | $18.07 | $11.23 | 350% |
RYTM - Will Rhythm Hit The Right Notes? | Feb. 18 | $7.52 | $30.98 | $26.38 | 312% |
VERU - Veru Gains On Efficacy Of COVID-19 Drug Candidate In Phase 3 Trial | Apr. 11 | $5.99 | $24.55 | $5.83 | 310% |
IMUX - Immunic's EMPhASIS Trial Data Published In Peer Reviewed Journal | Jun. 15 | $3.24 | $11.76 | $1.19 | 263% |
AMLX - FDA Panel Snubs Amylyx Pharma's Experimental ALS Drug | Mar. 31 | $11.68 | $39.78 | $37.04 | 241% |
DICE - DICE: Hit Or Miss? | Jun. 15 | $13.99 | $45.99 | $32.53 | 229% |
IMRA - Will IMARA Ace The Ardent And Forte Trials? | Mar. 14 | $1.61 | $5.26 | $3.84 | 227% |
AKRO - Will Akero's HARMONY Hit The Goals? | Mar. 7 | $15.34 | $48.24 | $43.60 | 214% |
SIGA - SIGA Rises 15% On Getting FDA Approval For IV Formulation Of TPOXX | May. 19 | $8.76 | $26.99 | $8.02 | 208% |
CELU - Celularity's NK Cell Therapy Awarded FDA's Fast Track Status For Yet Another Indication | Jan. 18 | $4.34 | $13.19 | $1.54 | 204% |
CVRX - Will CVRx Q1 Results Beat Or Lag Estimates? | Apr. 25 | $4.89 | $14.70 | $13.94 | 201% |
STIM - Neuronetics Expects 5% To 12% Revenue Growth In 2022 | May. 13 | $2.28 | $6.73 | $6.20 | 195% |
NERV - Minerva Seeks FDA Approval For Roluperidone In Treating Negative Symptoms Of Schizophrenia | Aug. 24 | $5.39 | $15.27 | $3.20 | 183% |
NVCT - What's Making News At Nuvectis? | Mar. 29 | $7.50 | $20.92 | $7.59 | 179% |
CTIC - CTI BioPharma Gets Speedy FDA Approval For Myelofibrosis Drug | Mar. 1 | $2.83 | $7.80 | $5.64 | 176% |
ABOS - INTERCEPT-AD Data Could Reveal ABOS' Acumen | Apr. 20 | $4.01 | $10.97 | $5.72 | 174% |
MHUA - Meihua International - Getting Back On Track? | Sep. 20 | $5.52 | $14.94 | $8.83 | 171% |
BIVI - Can BioVie Turn The Tables This Year? | Feb. 11 | $3.41 | $9.10 | $9.10 | 167% |
IMGO - Imago BioSciences Awaits Results Of Essential Thrombocythemia Trial | May. 15 | $14.39 | $35.89 | $35.87 | 149% |
MYOV - Myovant/Pfizer's Myfembree Awaits FDA Word - Go Or No Go? | Apr. 12 | $10.81 | $26.93 | $26.84 | 149% |
VTYX - Ventyx Biosciences Awaits VTX958 Trial Data | Aug. 11 | $17.19 | $41.29 | $27.11 | 140% |
NUVL - Will Nuvalent's ARROS-1 Hit The Target? | Aug. 10 | $17.00 | $40.43 | $31.56 | 138% |
AXSM - Axsome Therapeutics Soars On FDA's Labeling Of AXS-05 For Depressive Disorder | Jun. 27 | $34.62 | $80.87 | $77.85 | 134% |
PRVB - Will Teplizumab Be A Game Changer In The Diabetes Space? | Aug. 5 | $4.23 | $9.85 | $9.04 | 133% |
GOVX - GeoVax Issued Patent For Cancer Vaccine | Mar. 22 | $1.85 | $4.30 | $0.74 | 132% |
DBTX - Decibel Therapeutics Is Being Heard And Here's Why | Jun. 28 | $2.50 | $5.78 | $2.76 | 131% |
ANIX - Anixa's Ovarian Cancer CAR-T Therapy To Be Discussed At International Workshop On Apr.29 | Apr. 6 | $2.72 | $6.25 | $4.62 | 130% |
XFOR - X4 Pharma To Present Neutropenia Trial Data Today | Sep. 27 | $1.05 | $2.41 | $0.99 | 130% |
ATNM - Actinium Pharma Inks Deal With Immedica For Lead Drug Candidate Iomab-B | Apr. 12 | $6.59 | $15.12 | $11.05 | 129% |
LNTH - Lantheus Teams Up With Palette Life To Promote Prostate Cancer Diagnostic Imaging Agent | Feb. 24 | $38.28 | $87.47 | $53.51 | 129% |
DBVT - DBV Technologies To Provide Corporate Update Today | Mar. 3 | $1.51 | $3.43 | $1.31 | 127% |
VIGL - Vigil Neuroscience Notches Triple-digit Gains | Jul. 21 | $7.45 | $16.77 | $12.10 | 125% |
MGNX - MacroGenics Braces For A Busy 2H 2022 | Jul. 20 | $3.43 | $7.57 | $6.22 | 121% |
OLK - Olink Optimistic Of Robust Growth In 2022 | May. 24 | $11.32 | $24.93 | $22.52 | 120% |
SONX - Will Sonendo's Q4 Results Bring A Smile To Investors? | Mar. 14 | $3.15 | $6.84 | $2.90 | 117% |
PRPH - ProPhase Soars As Q1 Results Crush Estimates | May. 16 | $7.03 | $15.25 | $10.38 | 117% |
ORMP - Here's Why You Need To Keep An Eye On ORMP | May. 3 | $5.65 | $12.18 | $8.64 | 116% |
RXRX - After SYCAMOR, Recursion Pharma To Initiate POPLAR-NF2 In Q2 | Apr. 26 | $6.66 | $14.18 | $9.34 | 113% |
ACLX - Arcellx At The ASCO... | Jun. 3 | $12.66 | $26.91 | $21.68 | 113% |
MNPR - Will Monopar Make Its VOICE Heard? | May. 18 | $2.30 | $4.88 | $2.62 | 112% |
PRVA - Privia Health Confident About 2022 Growth Prospects | May. 13 | $21.09 | $44.64 | $23.13 | 112% |
AVEO - AVEO Expects Triple-digit Growth For Kidney Cancer Drug In FY22 | Jul. 7 | $7.20 | $14.95 | $14.89 | 108% |
FSTX - Will F-star Therapeutics Shine This Year? | Mar. 17 | $3.26 | $6.76 | $5.32 | 107% |
BLUE - Bluebird Bio - Not In The Pink Of Health? | Mar. 7 | $4.17 | $8.58 | $7.84 | 106% |
ALDX - Keep GUARD Over Aldeyra's TRANQUILITY... | Mar. 16 | $3.90 | $7.99 | $6.08 | 105% |
BLFS - BioLife Solutions Expects 34%-42% Revenue Growth In 2022 | May. 27 | $13.28 | $26.96 | $19.80 | 103% |
ESPR - Esperion's Q4 Net Product Revenue Jumps 49%; Data Readout Of CLEAR Outcomes Study In Q1, 2023 | Feb. 23 | $4.36 | $8.85 | $6.18 | 103% |
PCVX - Vaxcyte - An Ounce Of Prevention Is Worth A Pound Of Cure | Apr. 19 | $23.72 | $47.67 | $43.97 | 101% |